Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 15/20 | 0.51 |
| ▸ | QDPR | P09417 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230073 | 0.87 | MGLL (0.53) | MGLL | |
| SCHEMBL23215765 | 0.86 | HSP90AA1 (0.55) | MGLLQDPR | |
| SCHEMBL29745285 | 0.86 | HSP90AA1 (0.55) | MGLLQDPR | |
| SCHEMBL224986 | 0.84 | HSD11B1 (0.48) | MGLL | |
| SCHEMBL20855926 | 0.83 | CA1 (0.58) | MGLLCA1CA2 | |
| SCHEMBL10637954 | 0.83 | QDPR (0.49) | QDPR | |
| SCHEMBL10395236 | 0.82 | CPS1 (0.55) | MGLL | |
| SCHEMBL10638070 | 0.81 | CPS1 (0.57) | MGLLQDPR | |
| SCHEMBL26098997 | 0.80 | HSP90AA1 (0.66) | CA1CA2 | |
| SCHEMBL9823872 | 0.79 | ALDH1A1 (0.53) | MGLLCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491729-B2 | 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof | ABBOTT GMBH & CO. KG (DE) | 2009-02-17 | — | — | US | disclosed |
| EP-1572698-B1 | 3-SUBSTITUTED 3,4-DIHYDRO-THIENO¬2,3-D PYRIMIDINE-4-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF | ABBOTT GMBH & CO KG (DE) | 2008-07-02 | — | — | EP | disclosed |
| US-20060142317-A1 | 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-06-29 | — | — | US | disclosed |
| EP-1572698-A1 | 3-SUBSTITUTED 3,4-DIHYDRO-THIENO[2,3-D]PYRIMIDINE-4-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF | Abbott GmbH & Co. KG (DE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004055024-A1 | 3-SUBSTITUTED 3,4-DIHYDRO-THIENO[2,3-D]PYRIMIDINE-4-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142317-A1 | 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof | HTR3C, DRD3, HTR4 | MGLL 2091/4885QDPR 86/4885CA1 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.